Fortress Biotech, Inc.
NASDAQ: FBIOP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lindsay A. Rosenwald
- Employees
- 78
- Headquarters
- Bay Harbor Islands, United States
- IPO year
- 2017
- Market cap
- $158.5M
- Website
- https://www.fortressbiotech.com
Loading FBIOP…
Loading profile data…Frequently asked questions about FBIOP
What does Fortress Biotech, Inc. (FBIOP) do?
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis;...
Where does FBIOP trade?
Fortress Biotech, Inc. (FBIOP) trades on the NASDAQ.
What sector is FBIOP in?
Fortress Biotech, Inc. (FBIOP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Fortress Biotech, Inc.?
Lindsay A. Rosenwald is the chief executive officer of Fortress Biotech, Inc. (FBIOP).
Where is Fortress Biotech, Inc. headquartered?
Fortress Biotech, Inc. is headquartered in United States.
Does FBIOP pay a dividend?
Yes — Fortress Biotech, Inc. (FBIOP) paid a trailing twelve-month dividend of USD 2.34 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did FBIOP go public?
Fortress Biotech, Inc. (FBIOP) completed its initial public offering in 2017.